ABT - Abbott Laboratories
SNP 500


Strong Growth and ImprovingStock Price Attractive


based on last 5 year data.
Income Statement is STRONG
Revenue Growth is 13.21%
Operating Income Growth is 37.48%
Net Income Growth is 34.26%
Earnings Per Share (EPS) Growth is 34.93%
Net Margin is 18.71%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 2.01
Debt Ratio is 0.17
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.23
Cash Flow is STRONG
Cash from Operations Growth is -3.63%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is Low
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Abbott Laboratories (ABT) -
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Robert Ford
Employees - 109,000



Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2022 and future.